NMI 8739
Modify Date: 2024-01-09 11:08:39
NMI 8739 structure
|
Common Name | NMI 8739 | ||
|---|---|---|---|---|
| CAS Number | 129024-87-9 | Molecular Weight | 463.65100 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C30H41NO3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of NMI 8739NMI 8739 is a dopamine D2 autoreceptor agonist, which is an amine conjugate of the DHA carrier and the neurotransmitter dopamine. |
| Name | (4Z,7Z,10Z,13Z,16Z,19Z)-N-[2-(3,4-dihydroxyphenyl)ethyl]docosa-4,7,10,13,16,19-hexaenamide |
|---|---|
| Synonym | More Synonyms |
| Description | NMI 8739 is a dopamine D2 autoreceptor agonist, which is an amine conjugate of the DHA carrier and the neurotransmitter dopamine. |
|---|---|
| Related Catalog | |
| In Vitro | NMI 8739 is a dopamine D2 autoreceptor agonist[1], which is an amine conjugate of the DHA carrier and the neurotransmitter dopamine[2]. NMI 8739 reduces nitric oxide (NO) production in LPS-stimulated RAW264.7 Macrophages. NMI 8739 elicits concentration-dependent suppression of CCL-20, MCP-1 and IL-6 Release in RAW264.7 macrophages after LPS-stimulation. Production of PGE2 is concentration-dependently suppressed with a reduction of 25.3% at 100 nM NMI 8739 and a 75% reduction for 1 μM NMI 8739. 2 μM NMI 8739 significantly inhibits IL-6 and CCL-20 release up to 49% and 37%, respectively[3]. |
| References |
| Molecular Formula | C30H41NO3 |
|---|---|
| Molecular Weight | 463.65100 |
| Exact Mass | 463.30900 |
| PSA | 73.05000 |
| LogP | 8.07470 |
| Nmi 8739 |
| Dha-DA conjugate |
| 4,7,10,13,16,19-Docosahexaenoic acid dopamine conjugate |